Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Hakushindo Pharmaceutical Co., Ltd." found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Hakushindo Pharmaceutical Co., Ltd. for you to read. Along with our medical data and news we also list Hakushindo Pharmaceutical Co., Ltd. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Hakushindo Pharmaceutical Co., Ltd. Companies for you to search.
Company’s ioveraº System Offers Targeted, Long-Lasting Non-Opioid Pain Management Myoscience, a medical device company dedicated to relieving pain through targeted therapies, today announced that the company has entered into a definitive agreement for the acquisition of Myoscience by Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company d...
ReForm Biologics, a privately-held pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, today announced a collaboration with Astellas Pharma Inc. (TSE: 4503,”Astellas”) to reduce the viscosity of an Astellas
Bristol-Myers Squibb Company (NYSE:BMY) will take part in a fireside chat at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, in Boston. Giovanni Caforio, M.D., chairman and chief executive officer will answer
Researchers at the Statens Serum Institut, Copenhagen, the University of Copenhagen and Stanford University School of Medicine have completed the...Read More... The post Largest study to date finds no link between MMR vaccination and autism appeared first on Pharmaceutical Technology.
Catalyst Clinical Research, LLC (“Catalyst”), a leading provider of therapeutically-aligned, operational experts to pharmaceutical, biotechnology, and medical device companies in clinical development, acquired certain assets of Triangle Biostatistics, LLC (“Triangle”). With locations in Raleigh, NC and Wilmington, NC, Triangle is a leading provider...
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the following March investor conferences: Cowen 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 11:20 a.m. ET in Boston; and,
The approval of Alnylam Pharmaceuticals’ Onpattro (patisiran) and Ionis Pharmaceuticals Inc’s Tegsedi (inotersen sodium) in 2018 raised the possibility that...Read More... The post Big things are expected for RNA in 2019 appeared first on Pharmaceutical Technology.
ICON recognised for specialised services offering across product development lifecycle ICON plc, (NASDAQ: ICLR) a global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, has won awards across several categories in the annual CRO Leadership Awards. ICON receiv...
Agreement gives Iksuda access to Femtogenix’s therapeutic payloads to advance lead ADC for difficult-to-treat solid tumours Iksuda Therapeutics (Iksuda), the next-generation Antibody Drug Conjugate (ADC) company, today announced it has signed a licensing agreement with Femtogenix Limited (FGX), the next-generation ADC payload company. As part of this...
The work will be supported under a contract to Leidos from the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP). Leidos has been tasked The post GeoVax, Leidos expand collaboration to malaria vaccines appeared first on Pharmaceutical Business review.
The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9% The post Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China appeared first on Pharmaceutical Business review.
The phase IIIb trial compared Feraccru against Ferinject in 242 inflammatory bowel disease (IBD) patients whose iron deficiency anaemia (IDA) and haemoglobin (Hb) measurements are as low as The post Shield Therapeutics’Feraccru meets endpoints in anaemia trial appeared first on Pharmaceutical Business review.
Based in London, Nightstar is engaged in the development and commercialization of one-time treatments for patients with inherited retinal diseases. The company is mainly focused on the development The post Biogen to acquire UK-based Nightstar Therapeutics for $877m appeared first on Pharmaceutical Business review.
Numab Therapeutics AG today announced that Intarcia Therapeutics Inc. has executed its option to in-license ND016, being developed for the treatment of autoimmune disorders. Numab discovered ND016 on behalf of Intarcia under a previous research and option agreement. Under the present exclusive license agreement, Intarcia receives worldwide rights to develo...
Also known as RPL554, ensifentrine, is being investigated as an inhaled dual inhibitor of the phosphodiesterase 3 and 4 enzymes and is designed to have bronchodilator and anti-inflammatory The post Verona’s ensifentrine DPI formulation succeeds in part 1 of COPD trial appeared first on Pharmaceutical Business review.
The phase IIIb trial compared Feraccru against Ferinject in 242 inflammatory bowel disease (IBD) patients whose iron deficiency anaemia (IDA) and haemoglobin (Hb) measurements are as low as The post Shield Therapeutics’ Feraccru meets endpoints in anaemia trial appeared first on Pharmaceutical Business review.
Orion Corporation Press release 5 March 2019 at 8.00 a.m. EET Darolutamide submitted for marketing authorization in Japan Regulatory submission based on positive data from the Phase III ARAMIS trial Orion Corporation and Bayer today announced that an application for marketing authorization has been submitted to the ...
FDA Approves La Jolla’s Angiotensin 2 Reporter: Irina Robu, PhD In La Jolla Pharmaceutical Company’s new drug application (NDA) for angiotensin 2, the treatment was given priority review status by the FDA, advancing the application process to 6 months. The US Food and Drug Administration has approved an IV agent to treat critically-low blood pressure […]
This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the… The post Which pharma companies have the m... The post Which pharma companies have the most supplementary protection certificates? appeared first on Biotechblog.
Orion and Bayer have submitted an application to the Japanese Ministry of Health, Labor and Welfare (MHLW) seeking marketing authorisation...Read More... The post Orion and Bayer seek marketing clearance for darolutamide in Japan appeared first on Pharmaceutical Technology.
Top pharma executives testify before US Senate over high prices Top executives from seven major pharmaceutical companies have appeared before the...Read More... The post February’s top news stories appeared first on Pharmaceutical Technology.
Immunotherapy company NantKwest has partnered with ProMab Biotechnologies with the aim of developing a select next generation targeted natural killer...Read More... The post NantKwest and ProMab partner to develop NK cell therapies appeared first on Pharmaceutical Technology.
Global pharmaceutical leader Eli Lilly has announced plans to launch an authorised generic version of its insulin injection Humalog in...Read More... The post Lilly to introduce low-priced insulin generic in US appeared first on Pharmaceutical Technology.
With Boston and the surrounding area being one of the centers of the pharmaceutical world, it should come as no surprise that some of the top-selling medications are based in the Bay State.
San Diego-based Pacira Pharmaceuticals, a specialty pharmaceutical company, plunked down $220 million to acquire medical device company Myoscience and its non-opioid pain treatment system iovera.